TrialCompass™ TCL
Back to trials
RecruitingPriority 4 · Lower priorityNCT06588868

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This trial is testing an investigational treatment approach for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

Who can join (key eligibility)

  • Age 18 Years or older
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

What is CTCL?

Plain-language overview of CTCL plus all curated trials for this subtype.

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

NCT06588868

Status: Recruiting | Priority: Lower

Plain-language summary

This trial is testing an investigational treatment approach for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

Who can join

  • Age 18 Years or older
  • See full trial listing for complete eligibility

What's being tested

Drugs / treatments:

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 400 patients

Primary endpoint: To evaluate the different systemic treatment approaches in real life settings in patients with CTCL.; To evaluate the different systemic treatment approaches in real life settings in patients with CTCL.; To evaluate the different systemic treatment approaches in real life settings in patients with CTCL.

Ages: 18 Years to —

Start date: 2025-02-27 | Est. completion: 2026-07

Locations

0 US sites · 18 total

Contact

Uffici Studi FIL | startup@filinf.it | +390131033153

Sponsor: Fondazione Italiana Linfomi - ETS (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06588868

Prepared using TrialCompass (trialcompass.com) on August 3, 2026. For informational purposes only. Always discuss with your healthcare team.